Paraneoplastic Neurological Syndromes: Study of Prevalence in a Province of the Lombardy Region, Italy.
PNS epidemiology
PNS prevalence
cancer
paraneoplastic neurological syndrome
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Sep 2020
25 Sep 2020
Historique:
received:
07
08
2020
revised:
11
09
2020
accepted:
24
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
Paraneoplastic neurological syndromes (PNSs) are a heterogeneous group of rare immune-mediated diseases associated with cancer. The aim of this study was to investigate the prevalence of PNSs in the province of Brescia. PNS prevalence was calculated using the Lombardy regional hospital admission records from 1998 to 2003. We used the website "Epidemiologic and Economic Atlas of Hospital Activities in Lombardy" and the "International Statistical Classification of Diseases and Related Health Problems". In the province of Brescia, we found 54 cases of PNSs, 29 with subacute neuropathies, five with paraneoplastic cerebellar degeneration and 20 with encephalomyelitis. Peripheral nervous system diseases were the most frequent neurological disorders. In Lombardy, the number of PNS patients admitted was 322 (133 with encephalomyelitis, 21 with paraneoplastic cerebellar degeneration, 166 with polyneuropathies and two with optic degeneration). In Lombardy, the prevalence of PNSs was 25 in 100,000 hospital admissions and 5.92 in 100,000 for the Lombardy population. Our results show a discrete presence of PNS patients in the province of Brescia and in the Lombardy region as a whole.
Identifiants
pubmed: 32993010
pii: jcm9103105
doi: 10.3390/jcm9103105
pmc: PMC7599932
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurologist. 2009 Jan;15(1):21-33
pubmed: 19131854
Epidemiol Prev. 2017 Mar-Apr;41(2 Suppl 1):1-244
pubmed: 28629213
JAMA Neurol. 2016 Apr;73(4):417-24
pubmed: 26856612
Arch Neurol. 2010 Mar;67(3):330-5
pubmed: 20212230
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 26;7(6):
pubmed: 32847939
Bull Cancer. 2019 Jun;106(6):590-603
pubmed: 31072598
Curr Opin Neurol. 2007 Dec;20(6):732-7
pubmed: 17992098
J Neurol. 2017 Sep;264(9):1968-1977
pubmed: 28785798
Mayo Clin Proc. 2010 Sep;85(9):838-54
pubmed: 20810794
J Neurol. 2018 Jul;265(7):1590-1599
pubmed: 29725842
Continuum (Minneap Minn). 2019 Oct;25(5):1401-1421
pubmed: 31584543
Medicine (Baltimore). 2018 May;97(18):e0649
pubmed: 29718880
Acta Neurol Scand. 2012 Dec;126(6):365-75
pubmed: 22713136
J Neurol. 2020 Jan;267(1):26-35
pubmed: 31552550
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
pubmed: 15258215
J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1411-5
pubmed: 15377687
Neurol Clin. 2012 Feb;30(1):101-28, viii
pubmed: 22284057
J Neurooncol. 2015 Oct;125(1):197-206
pubmed: 26307447
PLoS One. 2017 Aug 2;12(8):e0181564
pubmed: 28767671
Lancet Neurol. 2008 Apr;7(4):327-40
pubmed: 18339348
Orphanet J Rare Dis. 2007 May 04;2:22
pubmed: 17480225
Lancet Neurol. 2007 Jan;6(1):75-86
pubmed: 17166804
Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1653-1679
pubmed: 29200116
Neurology. 2012 Sep 4;79(10):1049-55
pubmed: 22914826
Curr Opin Rheumatol. 2009 Nov;21(6):594-8
pubmed: 19730376
J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):449-58
pubmed: 2738587
Br J Dermatol. 2015 Apr;172(4):968-75
pubmed: 25388377
J Neurooncol. 2019 Jan;141(2):431-439
pubmed: 30607708
Lancet. 2004 Jun 26;363(9427):2151-61
pubmed: 15220040
Curr Opin Oncol. 2015 Nov;27(6):489-95
pubmed: 26335665
Intern Med J. 2018 Dec;48(12):1541-1542
pubmed: 30518000
Curr Clin Pharmacol. 2008 Jan;3(1):46-50
pubmed: 18690877
N Engl J Med. 2003 Oct 16;349(16):1543-54
pubmed: 14561798
Epidemiol Prev. 2014 Nov-Dec;38(6 Suppl 1):1-122
pubmed: 25759295
Int J Neurosci. 2018 Sep;128(9):821-827
pubmed: 29355452
Ann Neurol. 2018 Jan;83(1):166-177
pubmed: 29293273